Advanced Medical Solutions Group Regulatory News (AMS)

Advanced Medical Solutions Group plc

("AMS")

Notice of Preliminary Results

Winsford, UK: Advanced Medical Solutions Group plc (AIM: AMS.L), the global medical technology company, will announce its preliminary results for the year ended 31 December 2012 on Wednesday 6 March 2013.

A briefing for analysts will be held at 9.30am on the day of the results at the offices of Tavistock Communications, 131 Finsbury Pavement, London EC2A 1NT.

- ends -

For further information, please contact:

About Advanced Medical Solutions Group plc - see www.admedsol.com 

Founded in 1991, AMS is a leader in the development and manufacture of innovative and technologically advanced products for the US$15 billion global wound care market. Through a mix of organic development and a number of acquisitions, AMS now has a wide range of products based on technologies that include alginates, silver alginates, foams, collagens and cyanoacrylate adhesives (medical superglue).

AMS manufactures wound care products for an extensive list of Original Equipment Manufacturer ("OEM") customers around the world, but the majority of the Group's revenues now come from its own brands - ActivHeal® wound care products in the UK to the NHS, LiquiBand® cyanoacrylate products primarily in the UK, Europe and the USA, and RESORBA® sutures and collagen wound care products primarily in Europe.

AMS's products are sold globally via a network of regional or multinational partners and distributors, as well as via AMS's own direct sales forces in the UK, Germany, the Czech Republic and Russia.

With 450 employees operating under four distinct business units that match its multiple products and routes-to-market (Direct Brands, Distributed Brands, OEM Partner and Bulk Rollstock), AMS's products are manufactured from two sites in the UK, one in the Netherlands, two in Germany and one in the Czech Republic.